Depletion of plasmacytoid dendritic cells
Abstract:
The present invention relates to antibodies targeted to BDCA2 that deplete plasmacytoid dendritic cells (pDC) and methods of using the antibodies to treat disorders associated with pDC.
Public/Granted literature
Information query
Patent Agency Ranking
0/0